In RA patients who were treated with TNFα inhibiting agents (such as infliximab or etanercept) it was shown that blocking the effect of TNFα reversed the increased incidence of cardiovascular complications and insulin resistance (125–127). This evidence concerns the gene TNF and rheumatoid arthritis.